Clinical Trials

NCT Number: NCT06395519 Phase: PHASE1 Trial Summary: This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): 858 Therapeutics, Inc. Acronym: ERADIC8

NCT Number: NCT06397651 Phase: NA Trial Summary: A Decentralized, Double-blinded, Randomized, 18 month, Parallel-group, Superiority Study to evaluate the impact of Complement Theory’s Live 1:1 Exercise Coaching and Personalized Digital Application o – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Complement Theory Inc. Acronym:

NCT Number: NCT06402331 Phase: PHASE2|PHASE3 Trial Summary: This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Fusion Pharmaceuticals Inc. Acronym: AlphaBreak

NCT Number: NCT06200103 Phase: PHASE2 Trial Summary: This phase IV studies how to improve the use of Lu 177 vipivotide tetraxetan (177Lu-prostate-specific membrane antigen [PSMA]-617) for treating patients with castration-resistant prostate cancer tha – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Mayo Clinic Acronym:

NCT Number: NCT06212583 Phase: PHASE2 Trial Summary: The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of California, Davis Acronym: KNIGHTS

NCT Number: NCT06228053 Phase: PHASE2 Trial Summary: The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Syntrix Biosystems, Inc. Acronym: SYNERGY-201

NCT Number: NCT06235099 Phase: PHASE3 Trial Summary: This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation ther – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Curium US LLC Acronym: Solar-Recur

NCT Number: NCT06235151 Phase: PHASE3 Trial Summary: This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very h – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Curium US LLC Acronym: Solar-Stage

NCT Number: NCT06257264 Phase: PHASE1 Trial Summary: This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and pre – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): BeiGene Acronym:

NCT Number: NCT06305598 Phase: PHASE1 Trial Summary: This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate can – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Roswell Park Cancer Institute Acronym: